NPPB and cardiac hypertrophy: The use of dapagliflozin (DAPA) reduced the levels of markers of myocardial hypertrophy, ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide), markers of fibrosis (collagen I, fibronectin, and α-SMA).